Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Heron Therapeutics, Inc.

HRTX

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Last trade $0.2694
Day change -$0.0149 (-5.24%)
Day range $0.267 – $0.287
Volume 1,731,126
Market cap $54M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$53.28M
Price / earnings
—
Price / book
7.71×
Price / sales
0.35×
EV / sales
1.16×
EV / EBITDA
-20.07×

Profitability

Earnings per share
-$0.18
Return on assets
-13.5%
Return on equity
-492.89%
Dividend yield
0%

Liquidity and leverage

Debt / equity
20.65×
Current ratio
2.49×
Quick ratio
1.51×
Cash ratio
0.22×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HRTX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$37.67M$34.71M$40.59M$38.21M$37.2M$38.9M$40.78M$32.81M
Cost of revenue$11.57M$10.64M$11.12M$11.91M$9.86M$8.46M$10.23M$9.46M
Gross profit$26.09M$24.07M$29.47M$26.3M$27.34M$30.45M$30.55M$23.35M
Selling, general and administrative$25.44M$26.45M$25.69M$26.92M$26.05M$25.01M$23.2M$23.35M
Research and development$2.7M$2.39M$3.75M$3.47M$2.93M$2.28M$3.18M$4.47M
Total operating expenses$28.14M$28.84M$29.43M$30.39M$28.98M$27.29M$26.38M$27.81M
Operating income-$2.04M-$4.77M$38K-$4.09M-$1.64M$3.15M$4.17M-$4.46M
Interest expense$0$0-$9.61M$0$0$0-$6.03M$0
Income before taxes-$5.49M-$8.11M-$2.95M-$17.5M-$2.38M$2.64M$3.66M-$4.85M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.49M-$8.11M-$2.95M-$17.5M-$2.38M$2.64M$3.66M-$4.85M
Net income attributable to common shareholders-$5.49M-$8.11M-$2.95M-$17.5M-$2.38M$2.64M$3.66M-$4.85M
EBITDA-$1.59M-$4.24M$575K-$3.48M-$1.03M$3.71M$4.75M-$3.88M
Basic earnings per share-$0.03-$0.04-$0.02-$0.10-$0.02$0.02$0.02-$0.03
Diluted earnings per share-$0.03-$0.04-$0.02-$0.10-$0.02$0.01$0.02-$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates

Xencor (XNCR) reported quarterly earnings of $0.5 per share, significantly beating the consensus estimate of a loss of $0.35 per share, with revenues of $116.52 million surpassing estimates by 76.89%. Despite the strong earnings surprise of +242.86%, the stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The company has outperformed the S&P 500 by 100.1% year-to-date, but analysts expect underperformance in the near term.

GlobeNewswire Inc.

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Heron Therapeutics, Inc. announced it will host a conference call on November 9, 2026, to report third quarter financial results and discuss business highlights. The company reported Q2 2026 net revenue of $37.7 million, up 9% from Q1 2026, with ZYNRELEF net revenue growing 35% and APONVIE net revenue growing 74% year-over-year.

GlobeNewswire Inc.

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

Heron Therapeutics announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of investment management and corporate finance experience, most recently serving as a Managing Director at Starboard Value LP.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.